Trials / Completed
CompletedNCT00097955
Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 496 (planned)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Study of the efficacy and safety of aliskiren when added to losartan and optimal antihypertensive therapy in patients with hypertension, type 2 diabetes, and kidney disorders to monitor improvement in any of these conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | aliskiren |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2007-04-01
- Completion
- 2007-04-01
- First posted
- 2004-12-02
- Last updated
- 2017-05-17
Locations
12 sites across 12 countries: United States, Canada, Denmark, France, Germany, Greece, Italy, Netherlands, Romania, Russia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00097955. Inclusion in this directory is not an endorsement.